한글목차

세계의 흑색종 시장에 대해 조사했으며, 시장의 개요와 출시 치료법, 파이프라인 동향, 향후 전망 등을 제공하고 있습니다.

목차

개요

치료 알고리즘

조사 목적

출시 치료법

• 개요
• 면역치료
  • Opdivo/Yervoy(nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals)
  • Opdualag(nivolumab/relatlimab; Bristol Myers Squibb)
  • Keytruda(pembrolizumab; Merck & Co.)

BRAF/MEK 저해제

• 개요
  • 주요 인사이트 요약
  • Tafinlar/Mekinist(dabrafenib/trametinib; Novartis)
  • Cotellic/Zelboraf(cobimetinib/vemurafenib; Roche)
  • Braftovi/Mektovi(encorafenib/binimetinib; Pfizer)

종양용해성 바이러스/면역 자극제

• 개요
  • Imlygic(T-VEC/talimogene laherparepvec, Amgen)

종양 침윤 림프구(TIL) 세포치료

• 주요 인사이트 요약
  • Amtagvi(lifileucel; Iovance Biotherapeutics)

파이프라인 요법

면역 체크포인트 저해제

• 개요
  • 주요 인사이트 요약
  • BAL/BOT(balstilimab/botensilimab; Agenus)
  • Libtayo([cemiplimab)]/fianlimab; Regeneron)
  • Keytruda([pembrolizumab]/vibostolimab; Merck & Co.)

병변내 약제

• 개요
  • 주요 인사이트 요약
  • RP1(vsolimogene oderparepvec, Replimune)
  • Nidlegy(bifikafusp alfa + onfekafusp alfa; Philogen)
  • CMP 001(vidutolimod; Regeneron)

재조합 면역 자극제

• 개요
  • 주요 인사이트 요약
  • IO 102(IDOlong) /IO 103[PD-L1 펩티드 백신], IO Biotech
  • mRNA-4157(V940[맞춤형 암 백신], Moderna)

차세대 BRAF/MEK 저해제

• 개요
  • 주요 인사이트 요약
  • LXH 254(naporafenib, Erasca)
  • HL-085(tunlametinib, KeChow Pharma)

면역 세포 독성/T 림프구 자극제

• 개요
  • 주요 인사이트 요약
  • Kimmtrak(tebentafusp, Immunocore/Medison Pharma)
  • IMC-F106C(brenetafusp, Immunocore)

히스톤 탈아세틸화 효소(HDAC) 저해제

• 개요
  • 주요 인사이트 요약
  • Epidaza/Hiyasta(tucidinostat, HUYA Bioscience International)

중기/초기 단계 파이프라인

• 주요 인사이트 요약
  • 전문가가 암 면역치료의 유망한 최전선을 강조 : B7-H3, 이중특이성항체, 새로운 조합이 선도

부록

뉴스

영문목차

This report provides a comprehensive analysis of the current and future landscape of melanoma therapies. It delves into insights from key opinion leaders (KOLs) across the US, Australia, and Europe, focusing on the evolving roles of established treatments like Opdivo and Yervoy and emerging therapies. Gain an understanding of the latest clinical data, ongoing trials, and the impact of biosimilars on treatment accessibility. This report also explores the challenges and opportunities in personalised treatment strategies, offering a detailed view of how the melanoma treatment paradigm is expected to shift in the coming years.

Key questions answered:

• What are the preferred first- and subsequent-line melanoma treatments?
• How do current and pipeline therapies compare in efficacy and tolerability?
• What must pipeline therapies demonstrate to become the top choice?
• How will the use of melanoma therapies change by patient segment and preference?
• What efficacy and tolerability must pipeline products show to compete?
• Which promising pipeline candidates will impact current market players?
• How will melanoma treatment evolve for each therapy line?

Key brands covered in this report:

List of Companies:

Table of Contents

Executive summary

Treatment algorithm

Research objectives

Marketed therapies

• Overview
• Immunotherapies
  • Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals)
  • Opdualag (nivolumab/relatlimab; Bristol Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)

BRAF/MEK inhibitors

• Overview
  • Key insights summary
  • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
  • Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche)
  • Braftovi/Mektovi (encorafenib/binimetinib; Pfizer)

Oncolytic viruses/immunostimulants

• Overview
  • Imlygic (T-VEC/talimogene laherparepvec; Amgen)

Tumour infiltrating lymphocyte (TIL) cell therapy

• Key insights summary
  • Amtagvi (lifileucel; Iovance Biotherapeutics)

Pipeline therapies

Immune checkpoint inhibitors

• Overview
  • Key insights summary
  • BAL/BOT (balstilimab/botensilimab; Agenus)
  • Libtayo ([cemiplimab)]/fianlimab; Regeneron)
  • Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.)

Intralesional agents

• Overview
  • Key insights summary
  • RP1 (vusolimogene oderparepvec; Replimune)
  • Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen)
  • CMP 001 (vidutolimod; Regeneron)

Recombinant immunostimulants

• Overview
  • Key insights summary
  • IO 102 (IDOlong)/IO 103 [PD-L1 peptide vaccine]; IO Biotech)
  • mRNA-4157 (V940 [personalised cancer vaccine]; Moderna)

Next-generation BRAF/MEK inhibitors

• Overview
  • Key insights summary
  • LXH 254 (naporafenib; Erasca)
  • HL-085 (tunlametinib; KeChow Pharma)

Immunologic cytotoxicity/T lymphocyte stimulants

• Overview
  • Key insights summary
  • Kimmtrak (tebentafusp; Immunocore/Medison Pharma)
  • IMC-F106C (brenetafusp; Immunocore)

Histone deacetylase (HDAC) inhibitor

• Overview
  • Key insights summary
  • Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International)

Mid/early-stage pipeline

• Key insights summary
  • Experts highlight promising frontiers in cancer immunotherapy: B7-H3, bispecifics, and novel combinations lead the way

Appendix

• KOL details
  • KOLs from the Australia/USA
  • KOLs from Europe

News